Cyclacel Pharmaceuticals CYCC Stock
Cyclacel Pharmaceuticals Price Chart
Cyclacel Pharmaceuticals CYCC Financial and Trading Overview
| Cyclacel Pharmaceuticals stock price | 1.54 USD |
| Previous Close | 0.66 USD |
| Open | 0.65 USD |
| Bid | 0 USD x 900 |
| Ask | 0 USD x 800 |
| Day's Range | 0.65 - 0.69 USD |
| 52 Week Range | 0.5 - 2.41 USD |
| Volume | 24.96K USD |
| Avg. Volume | 49.85K USD |
| Market Cap | 8.33M USD |
| Beta (5Y Monthly) | 1.110563 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -26.75 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 13.5 USD |
CYCC Valuation Measures
| Enterprise Value | -3077135 USD |
| Trailing P/E | N/A |
| Forward P/E | -0.19763394 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 0.82082814 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | 0.108 |
Trading Information
Cyclacel Pharmaceuticals Stock Price History
| Beta (5Y Monthly) | 1.110563 |
| 52-Week Change | -49.23% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 2.41 USD |
| 52 Week Low | 0.5 USD |
| 50-Day Moving Average | 0.62 USD |
| 200-Day Moving Average | 0.91 USD |
CYCC Share Statistics
| Avg. Volume (3 month) | 49.85K USD |
| Avg. Daily Volume (10-Days) | 26.18K USD |
| Shares Outstanding | 12.54M |
| Float | 9.55M |
| Short Ratio | 7.37 |
| % Held by Insiders | 4.63% |
| % Held by Institutions | 32.58% |
| Shares Short | 508.02K |
| Short % of Float | 4.27% |
| Short % of Shares Outstanding | 4.04% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:20 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -57.57% |
| Return on Equity (ttm) | -105.11% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -28385000 USD |
| Net Income Avi to Common (ttm) | -23095000 USD |
| Diluted EPS (ttm) | -1.95 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 11.44M USD |
| Total Cash Per Share (mrq) | 0.91 USD |
| Total Debt (mrq) | 80K USD |
| Total Debt/Equity (mrq) | 0.79 USD |
| Current Ratio (mrq) | 2.586 |
| Book Value Per Share (mrq) | 0.809 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -20913000 USD |
| Levered Free Cash Flow (ttm) | -15678000 USD |
Profile of Cyclacel Pharmaceuticals
| Country | United States |
| State | NJ |
| City | Berkeley Heights |
| Address | 200 Connell Drive |
| ZIP | 07922 |
| Phone | 908 517 7330 |
| Website | https://www.cyclacel.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | N/A |
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company is headquartered in Berkeley Heights, New Jersey
Q&A For Cyclacel Pharmaceuticals Stock
What is a current CYCC stock price?
Cyclacel Pharmaceuticals CYCC stock price today per share is 1.54 USD.
How to purchase Cyclacel Pharmaceuticals stock?
You can buy CYCC shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Cyclacel Pharmaceuticals?
The stock symbol or ticker of Cyclacel Pharmaceuticals is CYCC.
Which industry does the Cyclacel Pharmaceuticals company belong to?
The Cyclacel Pharmaceuticals industry is Biotechnology.
How many shares does Cyclacel Pharmaceuticals have in circulation?
The max supply of Cyclacel Pharmaceuticals shares is 1.51M.
What is Cyclacel Pharmaceuticals Price to Earnings Ratio (PE Ratio)?
Cyclacel Pharmaceuticals PE Ratio is now.
What was Cyclacel Pharmaceuticals earnings per share over the trailing 12 months (TTM)?
Cyclacel Pharmaceuticals EPS is -26.75 USD over the trailing 12 months.
Which sector does the Cyclacel Pharmaceuticals company belong to?
The Cyclacel Pharmaceuticals sector is Healthcare.
Cyclacel Pharmaceuticals CYCC included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| NASDAQ Capital Market Composite RCMP | 114.55 USD — |
-2.27
|
— — | 114.09 USD — | 116.72 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
| NASDAQ Composite Total Return I XCMP | 19659.36 USD — |
-1.62
|
— — | 19598.88 USD — | 19861.56 USD — | — - | — — |
- {{ link.label }} {{link}}